Physician profile
Reid Johnstone
NPI 1013907260
$12,760.61
in general payments reported to CMS, 2019-2025
37 companies · $2,832 in 2025
The $2,832 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,118 · 2020: $960 · 2021: $2,236 · 2022: $1,775 · 2023: $1,715 · 2024: $2,124 · 2025: $2,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,638 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,637.83 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,295.07 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,076.64 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Csl Behring | $1,712.86 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Glaxosmithkline, LLC. | $1,294.66 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $1,028.75 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $889.52 | 2021-2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $642.14 | 2020-2025 | Takhzyro, Glassia, Cuvitru |
| Abbvie INC. | $445.98 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $299.32 | 2019-2025 | |
| Grifols USA, LLC | $292.09 | 2019-2025 | Xembify |
| Pharming Healthcare, INC. | $269.36 | 2021-2025 | Ruconest |
| Regeneron Healthcare Solutions, INC. | $212.29 | 2019-2025 | Dupixent |
| Leo Pharma INC. | $155.62 | 2022-2025 | Adbry |
| Kaleo, INC. | $124.15 | 2019-2024 | Auvi-Q |
| Hospira, INC. | $122.11 | 2021-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $106.54 | 2023-2025 | Tezspire |
| Alk-Abello, INC | $94.43 | 2019-2023 | Grastek, Ragwitek, Odactra |
| Ionis Pharmaceuticals, INC. | $78.46 | 2025 | Dawnzera |
| Lilly USA, LLC | $74.33 | 2025 | Ebglyss |
| Galderma Laboratories, L.P. | $58.84 | 2025 | Nemluvio |
| Optinose US, INC. | $54.18 | 2019-2025 | |
| Genentech USA, INC. | $50.24 | 2019-2023 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.01 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $37.28 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $36.43 | 2023-2024 | Ryaltris |
| Shire North American Group INC | $32.25 | 2019 | |
| Uswm, LLC | $30.24 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $26.57 | 2025 | Neffy |
| Cycle Pharmaceuticals INC | $25.40 | 2025 | Sajazir |
| Gc Biopharma USA, INC. | $24.14 | 2025 | Alyglo |
| Bio Products Laboratory USA, INC. | $24.03 | 2022 | |
| Merck Sharp & Dohme LLC | $21.55 | 2023 | |
| Incyte Corporation | $20.81 | 2022 | |
| Aerin Medical INC. | $20.39 | 2024 | |
| Biocryst Pharmaceuticals, INC. | $17.35 | 2020 | |
| Organon LLC | $15.36 | 2025 | Vtama |
| Octapharma USA, INC. | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reid Johnstone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.